News
VIVO
--
0.00%
--
Meridian Bioscience (VIVO) Outpaces Stock Market Gains: What You Should Know
Zacks.com · 1d ago
Cannabis Stock Gainers And Losers From May 7, 2021
GAINERS: Tetra Bio Pharma (OTC: TBPMF) shares closed up 22.62% at $0.38
Benzinga · 1d ago
Meridian Bioscience (VIVO) Beats Q2 Earnings Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 16.67% and -2.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
8-K: MERIDIAN BIOSCIENCE INC
(EDGAR Online via COMTEX) -- MERIDIAN BIOSCIENCE INC false 0000794172 0000794172 2021-05-07 2021-05-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
10-Q: MERIDIAN BIOSCIENCE INC
Edgar Online - (EDG = 10Q, 10K) · 2d ago
Meridian Bioscience, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 7, 2021 / Meridian Bioscience, Inc. (NASDAQ:VIVO) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on May 7, 2021 at 10:00 AM Eastern Time.
ACCESSWIRE · 2d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 2d ago
Meridian Bioscience Sees FY21 Adj. EPS $1.60-$1.80 vs $1.66 Est., Sales $305M-$355M vs $324.35M Est.
Adjusting Fiscal 2021 Guidance As a result of the voluntary withdrawal of the emergency use authorization (EUA) application for the Revogene SARS-CoV-2 assay in February, Meridian is adjusting the Diagnostics
Benzinga · 2d ago
Meridian Bioscience Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $85.30M Beat $84.48M Estimate
Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 143.48 percent increase over earnings of $0.23 per share
Benzinga · 2d ago
BRIEF-Meridian Bioscience Reports Strong Growth In Net Revenues And EPS In Q2 2021
reuters.com · 2d ago
Meridian Bioscience EPS beats by $0.09, misses on revenue
Meridian Bioscience (VIVO): FQ2 Non-GAAP EPS of $0.57 beats by $0.09; GAAP EPS of $0.61 beats by $0.18.Revenue of $85.26M (+48.8% Y/Y) misses by $1.98M.FY2021 Net Revenues:Consolidated $305 million to
Seekingalpha · 2d ago
Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021.
GlobeNewswire · 2d ago
Meridian Bioscience Adjusted Earnings, Net Revenue Rise in Fiscal Q2; Lowers FY21 Guidance
MT Newswires · 2d ago
Earnings Scheduled For May 7, 2021
  Companies Reporting Before The Bell • Cronos Group (NASDAQ:CRON) is likely to report earnings for its first quarter.
Benzinga · 2d ago
-- Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q2 Revenue $85.3M, vs. Street Est of $87.2M
MT Newswires · 2d ago
Global Hepatitis C Virus (HCV) Testing Market Size, Share, Value, And Competitive Landscape 2021 - 2026
May 07, 2021 (Heraldkeepers) -- The Hepatitis C Virus (HCV) Testing market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 2d ago
Point of Care Testing Market Size, Share, Trends, Analysis and Forecast 2027
May 06, 2021 (Market Insight Reports) -- The Global Point of Care Testing Market is estimated to value over USD 40.8 billion by 2027 end at a CAGR of over...
Market Insight Reports · 3d ago
Global Deoxynucleotide Triphosphates (dNTPs) Market Insights, Overview, Analysis and Forecast 2021-2027
May 06, 2021 (Heraldkeepers) -- Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive...
Heraldkeepers · 3d ago
Anti-microbial/Anti-fungal Tests Market Progression Status, Revenue Expectation to 2027
May 05, 2021 (MARKITWIRED via COMTEX) -- Microbial and fungal infections are a major cause of death globally and can even cause potential epidemics, creating...
Markitwired · 4d ago
Pneumonia Diagnostics Market Industry: A Latest Research Report to Share Market Insights and Dynamics 2021-2027
Heraldkeepers · 4d ago
Webull provides a variety of real-time VIVO stock news. You can receive the latest news about Meridian Biosci through multiple platforms. This information may help you make smarter investment decisions.
About VIVO
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.